Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
ID: HT9402-25-Q-9201Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYAURORA, CO, 80011, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/a09c18061a904b2f9fd03aae946167ba/view
Timeline
    Description

    The Department of Defense (DoD) is soliciting quotations for pharmaceutical agents as part of its Pharmacy Uniform Formulary Blanket Purchase Agreement and Additional Discount Program, managed by the Defense Health Agency (DHA). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the selection and classification of pharmaceutical agents based on clinical and cost-effectiveness for military beneficiaries. The upcoming Pharmacy and Therapeutics (P&T) Committee meeting, scheduled for May 7-8, 2025, will review specific drug classes, including Breast Cancer Agents and Targeted Immunomodulatory Biologics, with quotes due by March 20, 2025. Interested vendors should direct inquiries to Tracy Banks at tracy.e.banks2.civ@health.mil or Julianne Canaley at julianne.m.canaley.ctr@health.mil for further details.

    Point(s) of Contact
    Tracy Banks
    tracy.e.banks2.civ@health.mil
    Julianne Canaley
    julianne.m.canaley.ctr@health.mil
    Files
    Title
    Posted
    May 2025 PT Meeting Reporting.xlsx
    The Pharmacy Operations Support Contract (POSC) focuses on the management of pharmacy data within the Military Health System (MHS) utilizing the Pharmacy Data Transaction Service (PDTS). Vital patient information communication across Department of Defense (DoD) pharmacy services is emphasized, highlighting limitations in research capacity due to data update dynamics. Key challenges include tracking prescriptions not picked up by patients, categorizing dispensed prescriptions for acute versus chronic use, and the influence of a mobile population on prescription counts. The data set encompasses medication usages such as branded and generic drug identification, with dosage information critical for tracking. The report, titled "May 2025 P&T Meeting Reporting," covers data from January 1, 2024, to December 31, 2024, and provides specific examples of drug dispenses—such as Actemra (Tocilizumab) and Orencia (Abatacept)—with focus on quantities dispensed across various military treatment facilities (MTFs) and retail channels. The documentation underlines the importance of pharmacies adhering to procedural changes like supply limitations to ensure accurate data representation, which is essential for accurate claims processing and patient safety oversight within the DoD pharmacy landscape.
    NDC Price List - Breast Cancer - CDKI.xlsx
    The Department of Defense (DOD) is preparing for a Pharmacy and Therapeutics (P&T) Committee Meeting on May 7-8, 2025, regarding Breast Cancer Agents, specifically Cyclin Dependent Kinase Inhibitors. Quotes for the Blanket Purchase Agreement are due by March 20, 2025. The document outlines various scenarios for drug selection including uniform formulary (UF) and non-formulary options, stressing compliance with pricing and submission protocols for manufacturers. It notes the importance of prior authorization for certain agents and potential preferential treatment of non-generic drugs. The emphasized procedures aim to enhance the efficient dispensing of high-value medications while managing costs for the TRICARE pharmacy benefit program. Additionally, the document includes guidelines for providing necessary documentation and refund calculations. This initiative reflects the DOD's commitment to effective medication management for breast cancer treatment, focusing on cost efficiency and patient care.
    NDC Price List - TIBS - IL-1 IL-6 CTLA-4.xlsx
    The Department of Defense (DoD) is preparing for a P&T Committee meeting scheduled for May 7-8, 2025, focusing on the Uniform Formulary Class of Targeted Immunomodulatory Biologics. Drug quotes are due by March 20, 2025, to participate in the Blanket Purchase Agreement review process. The document outlines various scenarios involving formulary categories, prioritizing drugs based on their regulatory status—uniform or non-formulary options. It highlights the possibility of prior authorization requirements, potential preferential treatment for non-generic drugs, and the committee's authority to potentially exclude some drugs from the TRICARE program. Furthermore, it discusses step therapy protocols, which involve a required trial of preferred agents before accessing non-preferred options. The document informs manufacturers to submit fully executed signature pages with their quotes and emphasizes price standardization across different packaging sizes. The overarching aim is to enhance pharmaceutical management within military treatment facilities while ensuring cost-effectiveness and strategic use of pharmaceuticals within the DoD healthcare system.
    NDC Price List FAQ Class Review.pdf
    The Price Appendix FAQ provides guidelines for vendors participating in federal pricing quote submissions. It emphasizes the importance of understanding the Formulary Notes at the top of the spreadsheet to grasp the decision-making processes of the Pharmacy & Therapeutics (P&T) committee regarding formulary status. Vendors are instructed to fill in designated yellow cells, while other cells remain locked to maintain data integrity. For each National Drug Code (NDC) listed, vendors must enter the Package Size and Price per NDC, with automatic calculations for related fields simplifying the process. If a vendor opts not to submit a quote for specific conditions, the relevant cell will highlight red to inform the committee. The document accommodates submissions for up to ten NDCs per table and provides instructions on how to request additional tables if needed. The guidelines align with standard practices for government requests for proposals (RFPs) and federal grants, ensuring a structured and transparent bidding process. Vendors are encouraged to reach out to designated Points of Contact (POCs) for any inquiries or clarifications regarding the submission process, ensuring compliance and facilitating a smooth integration into the federal procurement framework.
    RFQ HT9402-25-Q-9201 CR.pdf
    The Department of Defense (DoD) is seeking quotations for pharmaceutical agents to be included in the Uniform Formulary (UF) as part of its integrated pharmacy benefits program. The Request for Quotation (RFQ) outlines the procedures for manufacturers to submit price quotes and refund offers, critical for determining drug classification and inclusion in the Basic Core Formulary (BCF) or Extended Core Formulary (ECF). Key elements include specifics on quoting for the Blanket Purchase Agreement (BPA) and the Additional Discount Program (ADP), which require detailed documentation including a National Drug Code (NDC) Price List. The DoD evaluates alternatives based on clinical effectiveness and cost-effectiveness to decide on agent inclusion within cost share tiers. The committee engages in a comprehensive review process, with established deadlines for submissions and the potential for discussions during a pre-quotation teleconference. Agencies like the Defense Health Agency (DHA) oversee the execution, with stringent requirements for pricing integrity and comparability against the Federal Supply Schedule. Ultimately, approvals hinge on achieving the best value for military beneficiaries while enabling manufacturers to participate in the TRICARE retail network. This strategic procurement initiative emphasizes collaboration between the DoD and pharmaceutical companies to optimize healthcare outcomes for service members.
    Similar Opportunities
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Doxycycline Hyclate Solicitation
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Doxycycline Hyclate tablets under solicitation number SPE2D2-25-R-0004. This procurement aims to secure pharmaceutical products in various quantities and packaging configurations, with a focus on compliance with federal regulations and quality control measures. Doxycycline Hyclate is a critical antibiotic used in various medical applications, making this procurement essential for maintaining adequate supplies for military and healthcare operations. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by February 5, 2025, and are encouraged to contact Courtney Hunter-Stangler or Jason C. Wray for further information regarding the solicitation.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Doxycycline Hyclate
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    Amendment 0003 Bicalutamide 50MG & 500MG tablets
    Buyer not available
    The Defense Logistics Agency (DLA) is soliciting proposals for a national requirements contract for Bicalutamide 50MG tablets, available in 30-count and 500-count bottles. The procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for various Department of Defense and other federal health programs. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base period and four one-year options, with an estimated annual quantity of 23,529 for the 30-count and 1,961 for the 500-count bottles. Interested parties should submit their proposals by February 7, 2025, at 3:00 PM, and can direct inquiries to Keith Ryales at keith.ryales@dla.mil or by phone at 215-737-9199.
    Famotidine
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    6505--Mycophenolate Mofetil RFP
    Buyer not available
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) numbered 36E79725R0010 for the procurement of Mycophenolate Mofetil tablets and capsules, intended for use by the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The procurement aims to secure a reliable source of supply for these essential medications, with a contract term of one year and the option to extend for four additional years, emphasizing the importance of uninterrupted access to critical pharmaceuticals for veterans and associated federal programs. Interested offerors must comply with specific packaging requirements, including child-resistant closures for smaller bottles, and are encouraged to check the designated URL for updates, with the solicitation expected to be issued around February 14, 2025, and offers accepted until February 28, 2025. For inquiries, potential bidders can contact Amber Zavala at amber.zavala@va.gov or by phone at (708) 786-5245.
    Pantoprazole DR Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Telmisartan Tablets
    Buyer not available
    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Telmisartan Tablets, a pharmaceutical product, to be delivered over multiple contract years. This solicitation, identified as SPE2D2-24-R-0015, requires compliance with various federal regulations, including the submission of a Subcontracting Plan for large businesses and adherence to Federal Acquisition Regulation (FAR) clauses concerning ethics and subcontracting practices. Telmisartan is crucial for managing hypertension and ensuring a reliable pharmaceutical supply is vital for military personnel's health. Interested vendors should submit their electronic proposals via the Defense Logistics Agency Internet Bid Board System (DIBBS) and can contact Courtney Hunter-Stangler at 215-737-6845 or via email at Courtney.Hunter-Stangler@dla.mil for further information.
    Valsartan
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.